|Podcasts|January 20, 2022

Industry Outlook 2022

Author(s)Elaine Quilici, Miranda Schmalfuhs

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor discussing various industry trends they've written up for our January issue.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

October 22nd, 2026

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

October 21st, 2026

Pharmaceutical Executive Daily: FDA Approves Hibsago

A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.

October 20th, 2026

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli

METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.

October 19th, 2026

Pharmaceutical Executive Daily: Hansoh Pharma Enters Collaboration and License Agreement with Roche for Broad Portfolio of ADCs

Merck KGaA, Darmstadt, Germany, acquires Silence Therapeutics for $1.3 billion, Hansoh Pharma and Roche expand their ADC partnership in a deal worth over $15 billion, and an EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe.

October 19th, 2026

Your Questions Answered: Foundayo’s EU Panel Backing, Enspryng for TED, Gilead’s Masked TCE Bet, FDA’s Rare Disease Overhaul, and More

Foundayo’s EU backing, Enspryng for TED, Gilead’s masked TCE deal, FDA’s rare disease reset, and Bausch + Lomb’s new interim CEO — explained.

October 14th, 2026

Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology

Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.

October 13th, 2026

Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche

Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.

Industry Outlook 2022

Related to this article

Trending on PharmExec

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds

CSL Names Deborah Waterhouse as CEO and Manager Director

The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals